BRAF and melanoma: A third BRAFi/MEKi combination (encorafenib/ binimetinib) has recently become commercially available in several regions, including the United States [19,20] and the European Union [21,22], based on the results from the COLUMBUS study, a large randomized phase III trial in patients with advanced BRAF-mutant melanoma [23].